Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands
© 2013 by Lippincott Williams & Wilkins. Background: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight...
Saved in:
相似書籍
-
Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands
由: Diane E.T. Bastiaans, et al.
出版: (2018) -
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
由: Kulkanya Chokephaibulkit, et al.
出版: (2018) -
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
由: Chokephaibulkit K., et al.
出版: (2014) -
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
由: Kulkanya Chokephaibulkit, et al.
出版: (2018) -
CRYSTALLOGRAPHIC STUDY ON DRUGS MIXTURE OF LOPINAVIR AND RITONAVIR
由: Budi Setianto, Arif